- Takeda Pharmaceutical Co Ltd TAK reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and lower acquisition-related expenses.
- Takeda exceeded its $10 billion non-core asset divestiture target and has announced 12 deals since January 2019 to date for a total aggregate value of up to $12.9 billion.
- Core net income expanded around 9% Y/Y to ¥655.5 billion.
- Operating profit grew 407.2% Y/Y to ¥509.3 billion, and core operating profit remained unchanged at ¥967.9 billion.
- Revenue of ¥3.2 trillion fell 2.8% from last year. On an underlying basis, revenue grew 2.2%, driven by the growth of Takeda's 14 global brands, up 16% Y/Y.
- The company's five key business areas — Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience — with ¥2.6 trillion reported revenue delivered Y/Y underlying revenue growth of 4.7%.
- At an underlying core operating profit margin of 30.2%, the company is also deleveraging, with a net debt/adjusted EBITDA ratio of 3.2x at the end of Q4, down from 3.8x in March 2020. Takeda is on course to meet its medium-term deleveraging goal of 2x within FY2021-FY2023.
- Operating cash flow increased by 50.9% to ¥1 trillion. Free cash flow ¥1.2 trillion representing an increase of 27.9% Y/Y.
- Guidance: For FY21, the company projects a net profit of ¥250 billion, core EPS of ¥394, operating profit of ¥488 billion, and core operating profit of ¥930 billion, all lower than FY20.
- However, revenue for the year is expected to be ¥3.4 trillion, +5.4% than last year.
- Takeda expects underlying revenue growth to accelerate to "mid-single-digit." Underlying core operating profit and underlying core EPS are expected to also grow at "mid-single-digit."
- Tt anticipates up to six regulatory submissions by year-end FY2021, with the potential for four approvals.
- Price Action: TAK shares closed 0.5% higher at $16.96 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
